Tandem Diabetes Care Stock Earnings Reports

Tandem reported a strong start to 2026 with record first-quarter pump shipments (~29,000) and sales of $247 million, driven by a 10% y/y increase in U.S. pump shipments. Management reaffirmed full-year 2026 guidance (worldwide sales $1.065–1.085B; U.S. $730–745M; international $335–340M), and expects 56–57% gross margin and 5–6% adjusted EBITDA for the year. Key strategic initiatives: (1) Commercial modernization and international go-direct expansion (launched direct ops in UK, Switzerland and Austria; additional markets planned in 2026–2027) to improve ASPs and margins; (2) U.S. multichannel shift to a Pay-as-You-Go (PayGo) pharmacy model—early commercial activity began in March, formulary coverage ~40% today, initial pharmacy channel orders and installed-base supply purchases each under 5% in the early weeks, and management remains confident in the multi-quarter transition and economics despite early operational friction; (3) product/technology progress—Tandem Mobi is now available with Android in the U.S.; FDA cleared Control‑IQ+ for use in pregnancy (first/only AID cleared for pregnancy in the U.S.); Abbott FreeStyle Libre 3+ integration and Dexcom G7 compatibility are coming in Q2; Mobi Tubeless 510(k) planned to be filed in Q2 with potential second‑half clearance and phased commercialization; pivotal fully closed‑loop study on track to start this year. Financial highlights: Q1 gross margin was 55% (best Q1 in company history), adjusted EBITDA ~1% of sales, operating expenses flat y/y, free cash flow $5M, $570M cash/investments following a $276M zero‑interest convertible debt raise. Risks/near‑term operational items: modest infusion‑set supplier shortages affecting a small set of SKUs and some customers (management expects resolution over several quarters), timing effects from international go‑direct transitions (Q2 headwinds of $3–4M noted), and an operational learning curve as PayGo is operationalized across prescribing, customer service and fulfillment.